Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Endurance RP ( (HK:0575) ) is now available.
Endurance RP announced significant progress in its operations, particularly with the NDA status for its product Senstend in China and advancements at Deep Longevity. The company’s strategic partner, Wanbang Biopharmaceutical, is optimistic about obtaining NDA approval by the end of 2025, which could lead to substantial financial gains for Endurance RP. Meanwhile, Deep Longevity is expanding its customer base and product offerings, aiming to capture a share of the growing longevity and wellness market, which is valued at over $6.3 trillion. These developments position Endurance RP for potential growth and increased market presence.
More about Endurance RP
Endurance RP, through its subsidiaries, operates in the pharmaceutical and biotechnology industries. It focuses on developing and commercializing treatments for premature ejaculation with its product Senstend, and is also involved in the longevity and wellness market through Deep Longevity, which develops artificial intelligence systems for aging and longevity medicine.
Average Trading Volume: 161,475
Technical Sentiment Signal: Hold
Current Market Cap: HK$242.2M
For a thorough assessment of 0575 stock, go to TipRanks’ Stock Analysis page.